SCP
ARQT icon

Silverleafe Capital Partners’s Arcutis Biotherapeutics ARQT Stock Holding History

Silverleafe Capital Partners’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-62,994
Closed -$1.83M – 104
2025
Q4 		$1.83M Buy
62,994
+46,366
+279% +$1.19M 0.54% 30
2025
Q3 		$313K Buy
16,628
+2,128
+15% +$33.6K 0.1% 74
2025
Q2 		$203K Sell
14,500
-11,708
-45% -$164K 0.07% 85
2025
Q1 		$410K Buy
+26,208
New +$369K 0.14% 59

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Silverleafe Capital Partners's ARQT Position: Q1 2026 in Review

Silverleafe Capital Partners sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 62,994 shares — an estimated $1.83M sold.

Silverleafe Capital Partners first reported a position in ARQT in Q1 2025 and held it in 4 quarters. The position peaked at $1.83M in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Silverleafe Capital Partners reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Silverleafe Capital Partners sold 62,994 Arcutis Biotherapeutics shares in Q1 2026, an estimated $1.83M.
  • Silverleafe Capital Partners first reported a position in Arcutis Biotherapeutics in Q1 2025 and held it in 4 quarters.
  • Silverleafe Capital Partners's Arcutis Biotherapeutics position peaked at $1.83M in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Silverleafe Capital Partners's 13F filing for Q1 2026, filed 2 Apr 2026.